{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:46Z","timestamp":1789674526339,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.msard.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T15:30:35Z","timestamp":1391873435000},"page":"419-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice"],"prefix":"10.1016","volume":"3","author":[{"given":"Robert L.","family":"Carruthers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.msard.2014.01.005_bib2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1080\/13550280390195388","article-title":"Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA)","volume":"9","author":"Antinori","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib3","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib4","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00415-012-6426-5","article-title":"Value of MRI as a surrogate marker for PML in natalizumab long-term therapy","volume":"259","author":"Ayzenberg","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.10827","article-title":"Changing incidence of central nervous system diseases in the EuroSIDA cohort","volume":"55","author":"d\u05f3Arminio Monforte","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/374048","article-title":"Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy","volume":"36","author":"Berenguer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib6","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000343735.44983.5e","article-title":"Steroids for PML-IRIS. A double-edged sword?","author":"Berger","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/13550280701469178","article-title":"Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient","volume":"13","author":"Bernal-Cano","year":"2007","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib11","article-title":"PML incidence in patients receiving Tysabri (natalizumab)","author":"BiogenIdec","year":"2013","journal-title":"Med Inf: Biogen I"},{"key":"10.1016\/j.msard.2014.01.005_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","article-title":"Natalizumab-associated PML entified in the presymptomatic phase using MRI surveillance","volume":"78","author":"Blair","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib13","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/1352458513481010","article-title":"Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab","volume":"19","author":"Blinkenberg","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jamaneurol.2013.1960","article-title":"Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab","volume":"70","author":"Boster","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol Clin"},{"key":"10.1016\/j.msard.2014.01.005_bib17","article-title":"Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy","author":"Carruthers","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneurol.2008.557","article-title":"Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy","volume":"66","author":"Cettomai","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/13550280260422758","article-title":"High incidence of JC viruria in JC-seropositive older individuals","volume":"8","author":"Chang","year":"2002","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/clinids\/24.3.526","article-title":"Idiopathic CD4+ T lymphocytopenia presenting as progressive multifocal leukoencephalopathy: case report","volume":"24","author":"Chikezie","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13550280152537247","article-title":"The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy","volume":"7","author":"Cinque","year":"2001","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib92","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"del Pilar Martin","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13550280601094563","article-title":"JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls","volume":"13","author":"Delbue","year":"2007","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2013.02.002","article-title":"Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia","volume":"327","author":"Delgado-Alvarado","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2014.01.005_bib29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.21277","article-title":"Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma","volume":"117","author":"Engels","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.msard.2014.01.005_bib30","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","article-title":"PML in a patient treated with fumaric acid","volume":"368","author":"Ermis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib31","unstructured":"FDA.gov. FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)."},{"key":"10.1016\/j.msard.2014.01.005_bib32","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","author":"Fine","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00002030-200307040-00004","article-title":"Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy","volume":"17","author":"Gasnault","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.msard.2014.01.005_bib34","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib36","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1086\/318120","article-title":"Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases","volume":"31","author":"Haider","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib37","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.msard.2014.01.005_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1352458508096870","article-title":"Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA","volume":"15","author":"Iacobaeus","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/jnnp.64.6.788","article-title":"An unusual course of progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia","volume":"64","author":"Iwase","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2014.01.005_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/13550280152537102","article-title":"A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region","volume":"7","author":"Jensen","year":"2001","journal-title":"J Neurovirol"},{"key":"10.1016\/j.msard.2014.01.005_bib41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib42","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaneurol.2013.3932","article-title":"ABO blood groups and risk for progressive multifocal leukoencephalopathy","volume":"70","author":"Khoury","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib44","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","article-title":"JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy","volume":"75","author":"Koralnik","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.msard.2014.01.005_bib45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib46","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e31823b9b27","article-title":"Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab treated MS patient","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy","volume":"4","author":"Linda","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib49","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib50","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1086\/374739","article-title":"The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study","volume":"187","author":"Ling","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib51","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/167.1.13","article-title":"Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects","volume":"167","author":"Markowitz","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib53","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","article-title":"In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection","volume":"81","author":"Martin-Blondel","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.22408","article-title":"Progressive multifocal leukoencephalopathy in transplant recipients","volume":"70","author":"Mateen","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","article-title":"Characterization of JC human polyomavirus infection in a Portuguese population","volume":"82","author":"Matos","year":"2010","journal-title":"J Med Virol."},{"key":"10.1016\/j.msard.2014.01.005_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/00207454.2012.760561","article-title":"A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing","volume":"123","author":"Mazda","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.msard.2014.01.005_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.msard.2014.01.005_bib58","series-title":"A French observational study about switching from natalizumab to fingolimod in multiple sclerosis","author":"Mikael Cohen","year":"2013"},{"key":"10.1016\/j.msard.2014.01.005_bib59","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis. Rheum."},{"key":"10.1016\/j.msard.2014.01.005_bib60","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u05f3Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib61","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/rheumatology\/kem049","article-title":"Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine","volume":"46","author":"Owczarczyk","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.msard.2014.01.005_bib63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.msard.2014.01.005_bib64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2014.01.005_bib65","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.msard.2014.01.005_bib66","series-title":"Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients","author":"Plavina T","year":"2013"},{"key":"10.1016\/j.msard.2014.01.005_bib67","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0028-3886.60423","article-title":"Progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+T lymphocytopenia","volume":"58","author":"Puri","year":"2010","journal-title":"Neurol India"},{"key":"10.1016\/j.msard.2014.01.005_bib68","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jmv.20829","article-title":"Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects","volume":"79","author":"Rossi","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/j.msard.2014.01.005_bib69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab-treated patients","volume":"68","author":"Rudick","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib70","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","article-title":"JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab","volume":"68","author":"Ryschkewitsch","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib71","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","article-title":"JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment","volume":"74","author":"Schippling","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib73","series-title":"Novel interventions with favorable resolution of natalizumab-indeced progressive multifocal leukoencephalopathy (PML)","author":"Stefoski","year":"2012"},{"key":"10.1016\/j.msard.2014.01.005_bib74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib75","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/597117","article-title":"Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation","volume":"199","author":"Tan","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib76","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00609-10","article-title":"JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy","volume":"84","author":"Tan","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.msard.2014.01.005_bib77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib78","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib79","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids","author":"Tan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib80","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/WNL.0b013e3182a84179","article-title":"Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient","volume":"81","author":"Tortorella","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib81","series-title":"Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis","author":"Tuan Dong-Si","year":"2013"},{"key":"10.1016\/j.msard.2014.01.005_bib82","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1352458512439238","article-title":"Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision","volume":"18","author":"Tur","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib1","unstructured":"Tysabri (natalizumab) prescribing information. Biogen Idec. Cambridge, MA; 2004."},{"key":"10.1016\/j.msard.2014.01.005_bib83","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u05f3s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib84","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib85","article-title":"Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients","author":"van Rossum","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.01.005_bib86","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/cid\/cir507","article-title":"JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals","volume":"53","author":"Viscidi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.msard.2014.01.005_bib150","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","article-title":"Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis","volume":"81","author":"Warnke","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.01.005_bib88","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2014.01.005_bib89","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","article-title":"Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons","volume":"65","author":"Wuthrich","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib90","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/NEN.0000000000000005","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study","volume":"72","author":"Wuthrich","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.msard.2014.01.005_bib91","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481400008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481400008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:36:40Z","timestamp":1761899800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481400008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S221103481400008X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2014.01.005","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}